Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.

Patel SH, Batchala PP, Mrachek EKS, Lopes MS, Schiff D, Fadul CE, Patrie JT, Jain R, Druzgal TJ, Williams ES.

Radiology. 2019 Nov 12:191140. doi: 10.1148/radiol.2019191140. [Epub ahead of print]

PMID:
31714193
2.

Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.

Nielsen T, Bernson D, Terplan M, Wakeman SE, Yule AM, Mehta PK, Bharel M, Diop H, Taveras EM, Wilens TE, Schiff DM.

Addiction. 2019 Nov 6. doi: 10.1111/add.14825. [Epub ahead of print]

PMID:
31692133
3.

Oligodendroglioma confers higher risk of radiation necrosis.

Ahmad H, Martin D, Patel SH, Donahue J, Lopes B, Purow B, Schiff D, Fadul CE.

J Neurooncol. 2019 Nov;145(2):309-319. doi: 10.1007/s11060-019-03297-7. Epub 2019 Sep 23.

PMID:
31549281
4.

Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.

Aliotta E, Batchala PP, Schiff D, Lopes BM, Druzgal JT, Mukherjee S, Patel SH.

J Neurooncol. 2019 Nov;145(2):257-263. doi: 10.1007/s11060-019-03291-z. Epub 2019 Sep 17.

PMID:
31531788
5.

Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.

Aliotta E, Nourzadeh H, Batchala PP, Schiff D, Lopes MB, Druzgal JT, Mukherjee S, Patel SH.

AJNR Am J Neuroradiol. 2019 Sep;40(9):1458-1463. doi: 10.3174/ajnr.A6162. Epub 2019 Aug 14.

PMID:
31413006
6.

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.

J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.

PMID:
31399936
7.

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D.

Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10.

PMID:
31290996
8.

Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.

Patel SH, Bansal AG, Young EB, Batchala PP, Patrie JT, Lopes MB, Jain R, Fadul CE, Schiff D.

AJNR Am J Neuroradiol. 2019 Jul;40(7):1149-1155. doi: 10.3174/ajnr.A6102. Epub 2019 Jun 27.

PMID:
31248860
9.

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH.

J Clin Oncol. 2019 Aug 10;37(23):2072-2081. doi: 10.1200/JCO.19.00327. Epub 2019 Jun 27.

PMID:
31246522
10.

Risk Factors for Drug Overdose in Young People: A Systematic Review of the Literature.

Lyons RM, Yule AM, Schiff D, Bagley SM, Wilens TE.

J Child Adolesc Psychopharmacol. 2019 Aug;29(7):487-497. doi: 10.1089/cap.2019.0013. Epub 2019 Jun 27.

PMID:
31246496
11.

Multimodality Therapy of Patients with Refractory Meningiomas.

Ahmad H, Schiff D.

Curr Treat Options Oncol. 2019 May 9;20(6):50. doi: 10.1007/s11864-019-0648-z. Review.

PMID:
31073797
12.

The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo.

Khan AJ, LaCava S, Mehta M, Schiff D, Thandoni A, Jhawar S, Danish S, Haffty BG, Chen S.

Oncotarget. 2019 Apr 19;10(29):2824-2834. doi: 10.18632/oncotarget.26854. eCollection 2019 Apr 19.

13.

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.

Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, Rooney B, Bell T, Lacayo NJ, Heym K, Degar B, Schiff D, Janssen WE, Triplett B, Pui CH, Leung W, Rubnitz JE.

J Immunother Cancer. 2019 Mar 20;7(1):81. doi: 10.1186/s40425-019-0564-6.

14.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
15.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
16.

How Should Clinicians Communicate With Patients About the Roles of Artificially Intelligent Team Members?

Schiff D, Borenstein J.

AMA J Ethics. 2019 Feb 1;21(2):E138-145. doi: 10.1001/amajethics.2019.138.

17.

Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.

Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.

Neuro Oncol. 2019 Feb 8. doi: 10.1093/neuonc/noz033. [Epub ahead of print]

PMID:
30753579
18.

Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant.

Schiff DM, Grossman MR.

Semin Fetal Neonatal Med. 2019 Apr;24(2):115-120. doi: 10.1016/j.siny.2019.01.003. Epub 2019 Jan 28. Review.

PMID:
30738754
19.

Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Batchala PP, Muttikkal TJE, Donahue JH, Patrie JT, Schiff D, Fadul CE, Mrachek EK, Lopes MB, Jain R, Patel SH.

AJNR Am J Neuroradiol. 2019 Mar;40(3):426-432. doi: 10.3174/ajnr.A5957. Epub 2019 Jan 31.

PMID:
30705071
20.

Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Sarkar RR, Gloude NJ, Schiff D, Murphy JD.

J Natl Cancer Inst. 2018 Dec 14. doi: 10.1093/jnci/djy193. [Epub ahead of print]

PMID:
30551196
21.

FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases.

Leiva-Salinas C, Muttikkal TJE, Flors L, Puig J, Wintermark M, Patrie JT, Rehm PK, Sheehan JP, Schiff D.

AJR Am J Roentgenol. 2019 Feb;212(2):425-430. doi: 10.2214/AJR.18.20006. Epub 2018 Nov 13.

PMID:
30422717
22.

Lower-grade gliomas: the wrong target for bevacizumab.

Schiff D, de Groot JF.

Neuro Oncol. 2018 Nov 12;20(12):1559-1560. doi: 10.1093/neuonc/noy165. No abstract available.

23.

The Joys and Frustrations of Breastfeeding and Rooming-In Among Mothers With Opioid Use Disorder: A Qualitative Study.

Howard MB, Wachman E, Levesque EM, Schiff DM, Kistin CJ, Parker MG.

Hosp Pediatr. 2018 Dec;8(12):761-768. doi: 10.1542/hpeds.2018-0116. Epub 2018 Nov 6.

24.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

25.

Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.

Wachman EM, Warden AH, Thomas Z, Thomas-Lewis JA, Shrestha H, Nikita FNU, Shaw D, Saia K, Schiff DM.

Drug Alcohol Depend. 2018 Nov 1;192:45-50. doi: 10.1016/j.drugalcdep.2018.07.024. Epub 2018 Sep 1.

PMID:
30205307
26.

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello C, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher I, Wulfkuhle J, Schiff D, Phan S, Petricoin E, Abounader R.

Clin Cancer Res. 2019 Jan 15;25(2):663-673. doi: 10.1158/1078-0432.CCR-18-0926. Epub 2018 Sep 10.

PMID:
30201763
27.

Stigmatizing Language About Neonatal Abstinence Syndrome.

Wakeman SE, Schiff DM, Gray J.

JAMA. 2018 Aug 21;320(7):722. doi: 10.1001/jama.2018.7808. No abstract available.

PMID:
30140867
28.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

PMID:
30137421
29.

Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression.

Huang RY, Unadkat P, Bi WL, George E, Preusser M, McCracken JD, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2019 Feb 14;21(2):234-241. doi: 10.1093/neuonc/noy126.

PMID:
30085283
30.

Neurologic and Medical Management of Brain Tumors.

Phillips KA, Fadul CE, Schiff D.

Neurol Clin. 2018 Aug;36(3):449-466. doi: 10.1016/j.ncl.2018.04.004. Epub 2018 May 29. Review.

PMID:
30072065
31.

Improved molecular karyotyping in glioblastoma.

Burbulis IE, Wierman MB, Wolpert M, Haakenson M, Lopes MB, Schiff D, Hicks J, Loe J, Ratan A, McConnell MJ.

Mutat Res. 2018 Sep;811:16-26. doi: 10.1016/j.mrfmmm.2018.06.002. Epub 2018 Jul 8.

PMID:
30055482
32.

Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.

Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, Bharel M, Wilens TE, LaRochelle M, Walley AY, Land T.

Obstet Gynecol. 2018 Aug;132(2):466-474. doi: 10.1097/AOG.0000000000002734.

33.

Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study.

Maldonado MD, Batchala P, Ornan D, Fadul C, Schiff D, Itri JN, Jain R, Patel SH.

J Neurooncol. 2018 Oct;140(1):107-113. doi: 10.1007/s11060-018-2939-9. Epub 2018 Jun 29.

PMID:
29959694
34.

VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells.

Khan AJ, Misenko SM, Thandoni A, Schiff D, Jhawar SR, Bunting SF, Haffty BG.

Oncotarget. 2018 May 25;9(40):25833-25841. doi: 10.18632/oncotarget.25383. eCollection 2018 May 25.

35.

Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R.

Cell Death Differ. 2019 Jan;26(1):197. doi: 10.1038/s41418-018-0145-0.

36.

ARTE and craft of bevacizumab in elderly patients with glioblastoma.

Schiff D.

Ann Oncol. 2018 Jun 1;29(6):1346-1347. doi: 10.1093/annonc/mdy136. No abstract available.

PMID:
29897386
37.

Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome.

Wachman EM, Grossman M, Schiff DM, Philipp BL, Minear S, Hutton E, Saia K, Nikita F, Khattab A, Nolin A, Alvarez C, Barry K, Combs G, Stickney D, Driscoll J, Humphreys R, Burke J, Farrell C, Shrestha H, Whalen BL.

J Perinatol. 2018 Aug;38(8):1114-1122. doi: 10.1038/s41372-018-0109-8. Epub 2018 May 8.

PMID:
29740196
38.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Sep 3;20(10):1411-1418. doi: 10.1093/neuonc/noy054.

39.

Examination of Hospital, Maternal, and Infant Characteristics Associated with Breastfeeding Initiation and Continuation Among Opioid-Exposed Mother-Infant Dyads.

Schiff DM, Wachman EM, Philipp B, Joseph K, Shrestha H, Taveras EM, Parker MGK.

Breastfeed Med. 2018 May;13(4):266-274. doi: 10.1089/bfm.2017.0172. Epub 2018 Apr 9.

40.

CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H, Scull B, Shih A, Lim KPH, Eckstein O, Lubega J, Peters TL, Olea W, Burke T, Ahmed N, Hicks MJ, Tran B, Jones J, Dauser R, Jeng M, Baiocchi R, Schiff D, Goldman S, Heym KM, Wilson H, Carcamo B, Kumar A, Rodriguez-Galindo C, Whipple NS, Campbell P, Murdoch G, Kofler J, Heales S, Malone M, Woltjer R, Quinn JF, Orchard P, Kruer MC, Jaffe R, Manz MG, Lira SA, Parsons DW, Merad M, Man TK, Allen CE.

Cancer. 2018 Jun 15;124(12):2607-2620. doi: 10.1002/cncr.31348. Epub 2018 Apr 6.

41.

Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment.

Wachman EM, Schiff DM, Silverstein M.

JAMA. 2018 Apr 3;319(13):1362-1374. doi: 10.1001/jama.2018.2640. Review.

PMID:
29614184
42.

Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report.

Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parulekar WR, Vogelbaum MA, Sahgal A.

Neuro Oncol. 2018 Aug 2;20(9):1215-1224. doi: 10.1093/neuonc/noy047.

43.

Maternal Health in the United States.

Schiff DM, Patrick SW, Terplan M.

N Engl J Med. 2018 Feb 8;378(6):587. doi: 10.1056/NEJMc1715957. No abstract available.

PMID:
29419278
44.

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Swinnen LJ, O'Neill A, Imus PH, Gujar S, Schiff D, Kleinberg LR, Advani RH, Dunbar EM, Moore D, Grossman SA.

Oncotarget. 2017 Nov 6;9(1):766-773. doi: 10.18632/oncotarget.22332. eCollection 2018 Jan 2.

45.

Encephalitis and Thalamic Injury From Neuroinvasive West Nile Virus in Children on Treatment for Acute Lymphoblastic Leukemia.

Farnaes L, Schiff D, McElroy AK, Coufal NG, Crawford JR, Cannavino C.

Pediatr Neurol. 2018 Mar;80:84-87. doi: 10.1016/j.pediatrneurol.2017.11.013. Epub 2017 Dec 2. No abstract available.

PMID:
29398166
46.

Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.

Taylor DG, Ilyas A, Mehta GU, Chen CJ, Schiff D, Oldfield EH, Asthagiri AR.

J Clin Neurosci. 2018 Apr;50:154-156. doi: 10.1016/j.jocn.2018.01.040. Epub 2018 Feb 1.

PMID:
29396065
47.

The siren song of bevacizumab: swan song or clarion call?

Schiff D, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):147-148. doi: 10.1093/neuonc/nox244. Review. No abstract available.

48.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

49.

Preface.

Schiff D, van den Bent MJ.

Handb Clin Neurol. 2018;149:ix. doi: 10.1016/B978-0-12-811161-1.09988-6. No abstract available.

PMID:
29307365
50.

Epidural and intramedullary spinal metastasis: clinical features and role of fractionated radiotherapy.

Rades D, Schiff D.

Handb Clin Neurol. 2018;149:227-238. doi: 10.1016/B978-0-12-811161-1.00015-3. Review.

PMID:
29307355

Supplemental Content

Loading ...
Support Center